Review finds greater heart risk in anti-smoking drug Chantix

07/5/2011 | Reuters

A meta-analysis in the Canadian Medical Association Journal found that healthy, middle-age users of Chantix, Pfizer's smoking-cessation drug, had a 72% greater risk of heart problems requiring hospitalization compared with placebo users. Last month, the FDA said Chantix's warning label will be revised to mention increased cardiovascular risk in those with a history of heart disease. Pfizer is working with the agency "to conduct a combined analysis of clinical-trial data" that "will help further evaluate the cardiovascular safety of Chantix," the company said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA